1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Physician Views: The idiopathic pulmonary fibrosis (IPF) market – let battle commence

Physician Views: The idiopathic pulmonary fibrosis (IPF) market – let battle commence

  • October 2014
  • ID: 2506823
  • Format: PDF
  • Firstword Pharma

Summary






The battle for market share in the US idiopathic pulmonary fibrosis (IPF) market is one that will be watched with much interest in 2015, with recent events setting the scene nicely.

The FDA recently simultaneously approved Roche's Esbriet and Boehringer Ingelheim's Ofev, and with both products set to launch within days, IPF patients (approximately 100 000 in the US) and pulmonologists will have access to recognised therapies for the first time.

Additional factors of note shaping this narrative include Roche's very recent acquisition of Esbriet (via its acquisition of InterMune in September) and the similar price tags, of around $95 000 per patient per year, set by the two companies for their respective products. There has already been some debate as to whether the price of these therapies will prompt payers to limit usage among less severe IPF patients.

At the crux of the commercial rivalry between Roche and Boehringer Ingelheim appears to be the perception that Esbriet is the better understood product (it had been submitted once before to the FDA on the basis of earlier study data), which has also demonstrated some superiority over Ofev in terms of mortality benefit. That said, the FDA has not included a statistically significant mortality benefit claim on Esbriet's label, which stems from a pooled analysis across two studies that has been published in the NEJM.








To provide further insight into the pending launches of Esbriet and Ofev, FirstWord is polling US-based pulmonologists with the following questions...


Which of the two recently approved IPF products - Esbriet (pirfenidone) and Ofev (nintedanib)- do you expect to prescribe most frequently?

To what percentage of eligible IPF patients would you expect to prescribe this product?
Can you select the factor(s) that will primarily dictate your choice of one product over the other from the below list?

• Efficacy – primary endpoints
• Efficacy – secondary endpoints
• Mortality benefit
• Safety
• Cost
• Previous experience with compound
• Previous experience with marketing company (Esbriet-Roche | Ofev – Boehringer Ingelheim)
• Other (please state)

Esbriet has been shown to provide a statistically significant mortality benefit as per a pre-defined analysis of pooled data (results published in the NEJM), but FDA labelling for the drug does not include this (the FDA requested a different statistical analysis compared to that published in the NEJM).Based on your current knowledge of both products (Esbriet and Ofev), what is your perception of any mortality benefit superiority for Esbriet?
• Extremely significant benefit
• Very significant benefit
• Moderately significant benefit
• Marginally significant benefit
• No benefit

What percentage of US IPF patients do you anticipate will have been treated with either Esbriet or Ofev in 12 months time (i.e. a year-post launch)?


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Gene Panel Market 2021-2025

  • $ 2500
  • June 2021
  • 120 pages

Global Gene Panel Market 2021-2025 The analyst has been monitoring the gene panel market and it is poised to grow by $ 2.17 billion during 2021-2025, progressing at a CAGR of almost 18% during the forecast ...

  • World
  • Targeted Therapy
  • Genetic Disorder
  • Industry analysis

ref:plp2014

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on